Outcomes in operative management of pancreatic cancer

Journal of Surgical Oncology

Volumn 110, Issue 5, 2014, Pages 592-598

  Bliss, Lindsay A ^a   Witkowski, Elan R ^b   Yang, Catherine J ^a   Tseng, Jennifer F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

outcomes; pancreatectomy; pancreatic cancer

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONFERENCE PAPER; HEALTH CARE DISPARITY; HEALTH CARE UTILIZATION; HISTORY OF MEDICINE; HUMAN; LAPAROSCOPY; LONG TERM SURVIVAL; MINIMALLY INVASIVE SURGERY; MORBIDITY; OUTCOME ASSESSMENT; PANCREAS CANCER; PANCREAS RESECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; ROBOTIC SURGICAL PROCEDURE; SURGICAL MORTALITY; SURVIVAL TIME; TERMINAL CARE; TUMOR GROWTH; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

HUMANS; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84921795471     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23744     Document Type: Conference Paper

References (75)

1. Witkowski ER, Smith JK, Tseng JF:, Outcomes following resection of pancreatic cancer. J Surg Oncol 2013; 107: 97-103.
2. Schnelldorfer T, Adams DB, Warshaw AL, et al.,: Forgotten pioneers of pancreatic surgery: Beyond the favorite few. Ann Surg 2008; 247: 191-202.
3. Whipple AO:, Pancreaticoduodenectomy for islet carcinoma: A five-year follow-up. Ann Surg 1945; 121: 847-852.
4. Rockey EW:, Total pancreatectomy for carcinoma: Case report. Ann Surg 1943; 118: 603-611.
5. Katz MH, Marsh R, Herman JM, et al.,: Borderline resectable pancreatic cancer: Need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013; 20: 2787-2795.
6. Callery MP, Chang KJ, Fishman EK, et al.,: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol 2009; 16: 1727-1733.
7. Gillen S, Schuster T, Friess H, et al.,: Palliative resections versus palliative bypass procedures in pancreatic cancer-a systematic review. Am J Surg 2012; 203: 496-502.
8. Howlader NNA, Kraphco M, et al.,: SEER cancer statistics review, 1975-2008. Institute NC: Bethesda, MD 2011.
9. Bilimoria KY, Bentrem DJ, Ko CY, et al.,: Validation of the 6th edition AJCC pancreatic cancer staging system-Report from the national cancer database. Cancer 2007; 110: 738-744.
10. Bilimoria KY, Bentrem DJ, Ko CY, et al.,: National failure to operate on early stage pancreatic cancer. Ann Surg 2007; 246: 173-180.
11. Pratt W, Joseph S, Callery MP, et al.,: Jr.: POSSUM accurately predicts morbidity for pancreatic resection. Surgery 2008; 143: 8-19.
12. Are C, Afuh C, Ravipati L, et al.,: Preoperative nomogram to predict risk of perioperative mortality following pancreatic resections for malignancy. J Gastrointest Surg 2009; 13: 2152-2161.
13. Hill JS, Zhou Z, Simons JP, et al.,: A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol 2010; 17: 1802-1807.
14. Kelly KJ, Greenblatt DY, Wan Y, et al.,: Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: Preoperative factors predict morbidity and mortality. J Gastrointest Surg 2011; 15: 250-259 discussion 259-261.
15. Greenblatt DY, Kelly KJ, Rajamanickam V, et al.,: Preoperative factors predict perioperative morbidity and mortality after pancreaticoduodenectomy. Ann Surg Oncol 2011; 18: 2126-2135.
16. Venkat R, Edil BH, Schulick RD, et al.,: Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: A systematic review and meta-analysis. Ann Surg 2012; 255: 1048-1059.
17. Kimura W, Miyata H, Gotoh M, et al.,: A Pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: The 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg 2014; 259: 773-780.
18. Vollmer CM, Sanchez N, Gondek S, et al.,: A root-cause analysis of mortality following major pancreatectomy. J Gastrointest Surg 2012; 16: 89-102.
19. McPhee JT, Hill JS, Whalen GF, et al.,: Perioperative mortality for pancreatectomy-A national perspective. Ann Surg 2007; 246: 246-253.
20. Sohn TA, Lillemoe KD:, Surgical palliation of pancreatic cancer. Adv Surg 2000; 34: 249-271.
21. Trede M, Schwall G, Saeger HD:, Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-458.
22. Winter JM, Brennan MF, Tang LH, et al.,: Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol 2012; 19: 169-175.
23. Birkmeyer JD, Siewers AE, Finlayson EV, et al.,: Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
24. Balcom JHt, Rattner DW, Warshaw AL, et al.,: Ten-year experience with 733 pancreatic resections: Changing indications, older patients, and decreasing length of hospitalization. Arch Surg (Chicago, Ill: 1960) 2001; 136: 391-398.
25. Hill JS, McPhee JT, Whalen GF, et al.,: In-hospital mortality after pancreatic resection for chronic pancreatitis: Population-based estimates from the nationwide inpatient sample. J Am Coll Surg 2009; 209: 468-476.
26. Carroll JE, Smith JK, Simons JP, et al.,: Redefining mortality after pancreatic cancer resection. J Gastrointest Surg 2010; 14: 1701-1708.
27. Bassi C, Dervenis C, Butturini G, et al.,: Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 2005; 138: 8-13.
28. Simons JP, Shah SA, Ng SC, et al.,: National complication rates after pancreatectomy: Beyond mere mortality. J Gastrointest Surg 2009; 13: 1798-1805.
29. Simons JP, Ng SC, McDade TP, et al.,: Progress for resectable pancreatic [corrected] cancer?: A population-based assessment of US practices. Cancer 2010; 116: 1681-1690.
30. Kent TS, Sachs TE, Callery MP, et al.,: Readmission after major pancreatic resection: A necessary evil ? J Am Coll of Surg 2011; 213: 515-523.
31. Hyder O, Dodson RM, Nathan H, et al.,: Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. JAMA surgery 2013; 148: 1095-1102.
32. Riall TS, Cameron JL, Lillemoe KD, et al.,: Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 2006; 140: 764-772.
33. Riall TS, Nealon WH, Goodwin JS, et al.,: Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 2006; 10: 1212-1223 discussion 1223-1214.
34. Zhang JF, Hua R, Sun YW, et al.,: Influence of perineural invasion on survival and recurrence in patients with resected pancreatic cancer. Asian Pac J Cancer Prev 2013; 14: 5133-5139.
35. van der Gaag NA, Harmsen K, Eshuis WJ, et al.,: Pancreatoduodenectomy associated complications influence cancer recurrence and time interval to death. Eur J Surg Oncol 2013.
36. Nordby T, Hugenschmidt H, Fagerland MW, et al.,: Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol 2013; 39: 559-566.
37. Sheffield KM, Crowell KT, Lin YL, et al.,: Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol 2012; 19: 1670-1677.
38. Birkmeyer JD, Sun Y, Wong SL, et al.,: Hospital volume and late survival after cancer surgery. Ann Surgery 2007; 245: 777-783.
39. Hawasli A:, Laparoscopic cholecysto-jejunostomy for obstructing pancreatic cancer: technique and report of two cases. J Laparoendosc Surg 1992; 2: 351-355.
40. Vijan SS, Ahmed KA, Harmsen WS, et al.,: Laparoscopic vs open distal pancreatectomy: A single-institution comparative study. Arch Surg (Chicago, Ill: 1960) 2010; 145: 616-621.
41. Magge D, Gooding W, Choudry H, et al.,: Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA surgery 2013; 148: 525-531.
42. Stauffer JA, Rosales-Velderrain A, Goldberg RF, et al.,: Comparison of open with laparoscopic distal pancreatectomy: A single institution's transition over a 7-year period. HPB 2013; 15: 149-155.
43. Correa-Gallego C, Dinkelspiel HE, Sulimanoff I, et al.,: Minimally-invasive vs open pancreaticoduodenectomy: Systematic review and meta-analysis. J Am Coll Surg 2014; 218: 129-139.
44. Kendrick ML, Sclabas GM:, Major venous resection during total laparoscopic pancreaticoduodenectomy. HPB 2011; 13: 454-458.
45. Zureikat AH, Moser AJ, Boone BA, et al.,: 250 robotic pancreatic resections: Safety and feasibility. Ann Surg 2013; 258: 554-559; discussion 559-562.
46. O'Connell JB, Maggard MA, Ko CY:, Cancer-directed surgery for localized disease: Decreased use in the elderly. Ann Surg Oncol 2004; 11: 962-969.
47. Baxter NN, Whitson BA, Tuttle TM:, Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007; 14: 1320-1326.
48. Murphy MM, Simons JP, Hill JS, et al.,: Pancreatic resection a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer 2009; 115: 3979-3990.
49. Murphy MM, Simons JP, Ng SC, et al.,: Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol 2009; 16: 2968-2977.
50. Bliss LA, Yang CJ, Chau Z, et al.,: Patient selection and the volume effect in pancreatic surgery: unequal benefits ? HPB 2014; Epub.
51. Shah A, Chao KS, Ostbye T, et al.,: Trends in racial disparities in pancreatic cancer surgery. J Gastrointestinal Surg 2013; 17: 1897-1906.
52. Lee S, Reha JL, Tzeng CW, et al.,: Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol 2013; 20: 4073-4079.
53. Seyedin S, Luu C, Stabile BE, et al.,: Effect of socioeconomic status on surgery for pancreatic adenocarcinoma. Am Surg 2012; 78: 1128-1131.
54. Sandroussi C, Brace C, Kennedy ED, et al.,: Sociodemographics and comorbidities influence decisions to undergo pancreatic resection for neoplastic lesions. J Gastrointest Surg 2010; 14: 1401-1408.
55. Sheffield KM, Boyd CA, Benarroch-Gampel J, et al.,: End-of-life care in medicare beneficiaries dying with pancreatic cancer. Cancer 2011; 117: 5003-5012.
56. Earle CC, Landrum MB, Souza JM, et al.,: Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue ? J Clin Oncol 2008; 26: 3860-3866.
57. Rees JR, Macefield RC, Blencowe NS, et al.,: A prospective study of patient reported outcomes in pancreatic and peri-ampullary malignancy. World J Surg 2013; 37: 2443-2453.
58. Network NCC: NCCN Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (Version 2.2012). 2012.
59. Raigani S, Ammori J, Kim J, et al.,: Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg 2014; 18: 113-123.
60. Conroy T, Desseigne F, Ychou M, et al.,: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
61. Rhim AD, Mirek ET, Aiello NM, et al.,: EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148: 349-361.
62. Kadera BE, Sunjaya DB, Isacoff WH, et al.,: Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA surgery 2014; 149: 145-153.
63. Festa V, Andriulli A, Valvano MR, et al.,: Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of prospective studies. JOP 2013; 14: 618-625.
64. Chua TC, Saxena A:, Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results. Surg Oncol 2011; 20: e161-168.
65. Barugola G, Partelli S, Crippa S, et al.,: Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Am J Surg 2012; 203: 132-139.
66. Haeno H, Gonen M, Davis MB, et al.,: Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375.
67. Simons JP, Ng SC, McDade TP, et al.,: Progress for resectable cancer? A population-based assessment of US practices. Cancer 2010; 116: 1681-1690.
68. Herman JM, Swartz MJ, Hsu CC, et al.,: Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510.
69. Corsini MM, Miller RC, Haddock MG, et al.,: Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: The mayo clinic experience (1975-2005). J Clin Oncol 2008; 26: 3511-3516.
70. Merchant NB, Rymer J, Koehler EA, et al.,: Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: Who really benefits ? J Am Coll Surg 2009; 208: 829-838 discussion 838-841.
71. Piperdi M, McDade TP, Shim JK, et al.,: A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: Lessons from a single-institution database. HPB 2010; 12: 204-210.
72. Kent TS, Sachs TE, Sanchez N, et al.,: Conditional survival in pancreatic cancer: Better than expected. HPB 2011; 13: 876-880.
73. Merkow RP, Bilimoria KY, Tomlinson JS, et al.,: Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2013.
74. Evans DB, Varadhachary GR, Crane CH, et al.,: Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-3502.
75. Varadhachary GR, Wolff RA, Crane CH, et al.,: Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.